This agreement will ensure Australian psychiatrists and researchers have affordable access to GMP grade medicines for clinical trials and the TGA’s Authorised Prescriber Scheme, which begins from July 1, 2023.
Read our press release for more details here.
Registered health professionals and researchers in Australia can fill out the EOI form below, and a member of our team will reach out to provide further details.
Optimi Health Corp.
21 Water St #600, Vancouver, BC V6B 1A1
Legal Counsel: Norton Rose Fulbright
Auditor: Smythe CPA
Transfer Agent: Endeavor Trust
Corporate Visibility & Investor Relations: Kydder Group
Trading Symbol: CSE: OPTI | OTC:OPTHF |
CUSIP Number: 68405H100
ISIN Number: CA68405H1001
Issued & Outstanding: (30/06/2022) 80,451,883
Incorporated: BC / May 27, 2020
Year End: September 30th
Products do not contain psilocybin